$750M 7.7%
Total revenue, Q2 '26 ().

Did Conduit Pharmaceuticals Beat Earnings?

Conduit Pharmaceuticals (CDT) reported Q2 '26 revenue of $750M, up 11.6% year-over-year.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Conduit Pharmaceuticals’s job postings, web traffic, and employee business outlook. See the full CDT stock analysis or the earnings calendar for upcoming reports.

Conduit Pharmaceuticals Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue655M1.08B625M672M698M2.72B696M750M
Gross margin0.0%0.0%0.0%-0.1%-0.1%0.0%37.1%40.1%
Operating margin-0.9%-0.3%-0.6%-0.7%-1.0%-0.8%11.2%15.6%
Net income-6.5M-2.4M-4.8M-6M-7.1M-21M51M69M
Net margin-1.0%-0.2%-0.8%-0.9%-1.0%-0.8%7.3%9.1%
EPS

Conduit Pharmaceuticals Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Conduit Pharmaceuticals’s quarterly revenue moved from $655M to $750M. Net margin expanded from -1% to 9.1%, against a 40.1% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit.

When Is Conduit Pharmaceuticals’s Next Earnings Date?

Conduit Pharmaceuticals reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the CDT earnings calendar.

Frequently Asked Questions: Conduit Pharmaceuticals Earnings

Conduit Pharmaceuticals's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Conduit Pharmaceuticals reported Q2 '26 revenue of $750M, up 11.6% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the CDT AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.